No Picture
News

FDA Grants AlgoTx IND Clearance for Phase 2 Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy

SURESNES, France–(BUSINESS WIRE)–European biotech AlgoTx, an innovator in complex pain therapy, today announces the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug Application (IND) for Phase 2 candidate ATX01 in the trea… […]

No Picture
News

Enspectra Health announces new VISION trial and partnership with Golden State Dermatology

MOUNTAIN VIEW, Calif., June 1, 2022 /PRNewswire/ — Enspectra Health, a digital health company dedicated to pioneering a new field of virtual biopsies, announced today that it has launched a pilot feasibility study. The study, named VISION, will evalua… […]

No Picture
News

New Podcast from Mindfulness Exercises Inspires Self-Compassion, Presence and Resilience in these Challenging Times

BERKELEY, Calif., June 1, 2022 /PRNewswire/ — A hotly anticipated mindfulness podcast has launched in response to an urgent need for innovative tools to cope with stress during these challenging times. “Now more than ever, with stressors and addiction… […]

No Picture
News

Therapy Brands Partners with BetterHelp to Expand Access to Quality Mental Healthcare, Connecting More Patients to Mental and Behavioral Health Practitioners

BIRMINGHAM, Ala. and MOUNTAIN VIEW, Calif., June 1, 2022 /PRNewswire/ — Therapy Brands, and BetterHelp, announce a new partnership with designed to connect consumers directly to certified and accredited therapists. Leveraging their flagship practice m… […]

No Picture
News

Excelin Health, a portfolio company of Corinthian Equity Fund II, L.P., completes third acquisition in the last 7 months with the acquisition of Bay Area home healthcare provider On My Care

NEW YORK, June 1, 2022 /PRNewswire/ — Excelin Health (“Excelin”), a superregional home health and hospice platform, is pleased to announce the purchase of On My Care, a Fremont, CA-based agency providing skilled nursing, physical, occupational, and sp… […]

No Picture
News

MyOme Presents New Data at ASCO 2022 on Cross-ancestry Polygenic Risk Score for Breast Cancer

Study highlights potential of Polygenic Risk Scores (PRS) to improve breast cancer risk assessment in women across multiple ancestries MENLO PARK, Calif., June 1, 2022 /PRNewswire/ — MyOme, a clinical whole genome platform analysis company, today anno… […]